甲基多巴联合拉贝洛尔治疗妊娠期高血压的疗效观察

目的观察甲基多巴联合拉贝洛尔治疗妊娠期高血压的临床疗效。方法将84例妊娠期高血压患者根据治疗方法不同分为对照组和观察组,各42例。对照组采用常规治疗及硫酸镁治疗,观察组在对照组基础上采用甲基多巴联合拉贝洛尔治疗。两组均连续治疗7 d,比较两组的心脏指数(CI)、总外周阻力(TPR)、脐动脉血流S/D及不良反应情况。结果治疗后,两组的CI高于治疗前,TPR、脐动脉血流S/D均低于治疗前,且观察组的CI高于对照组,TPR、脐动脉血流S/D均低于对照组(P均<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论甲基多巴联合拉贝洛尔治疗妊娠期高血压的效果显著,有利于提高患者的CI,降低TPR及脐动脉血流S/D,且不会增加不良反应。

Observation on Efficacy of Methyldopa Combined with Labetalol in the Treatment of Pregnancy-Induced Hypertension

Objective To observe the clinical efficacy of methyldopa combined with labetalol in the treatment of pregnancy-induced hypertension. Methods 84 patients with pregnancy-induced hypertension were divided into control group and observation group according to different treatment methods, with 42 cases in each group. The control group was given routine treatment and magnesium sulfate. The observation group was treated with methyldopa combined with labetalol on the basis of the control group. Both groups were treated continuously for 7 days. The cardiac index(CI), total peripheral resistance(TPR), umbilical artery blood flow S/D before and after treatment and adverse reactions were compared between the two groups. Results After treatment, the CI of the two groups were higher than those before treatment, and the TPR and umbilical arterial blood flow S/D were lower than those before treatment(all P <0.05);The CI of the observation group was higher than that of the control group, and the TPR and umbilical arterial blood flow S/D were lower than those of the control group(all P <0.05). No statistical difference was found in the incidence of adverse reactions between the two groups(P >0.05).Conclusions Methyldopa combined with labetalol has significant effect in the treatment of pregnancy-induced hypertension, which is conducive to improving the CI, and reducing the TPR and umbilical arterial blood flow S/D, without increasing the adverse reactions.